Bogdan Kałużewski

Prof. Bogdan Kałużewski

Co-owner of “Genos” Partnership, Inowrocławska Str. 9/132, 91-033 Lodz, Poland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ETEwa Tyczkowska-Sieroń
Ewa Tyczkowska-Sieroń
TKTadeusz Kałużewski
Tadeusz Kałużewski
MGMagdalena Grabiec
Magdalena Grabiec
Bogdan KałużewskiBogdan Kałużewski
Bogdan Kałużewski
Jacek TyczkowskiJacek Tyczkowski
Jacek Tyczkowski
We treated Candida albicans cells with a sublethal dose of nonequilibrium (cold) atmospheric-pressure He plasma and studied alterations in the genome of this fungus as well as changes in the phenotypic traits, such as assimilation of carbon from carbohydrates, hydrolytic enzyme activity, and drug susceptibility. There is a general problem if we use cold plasma to kill microorganism cells and some of them survive the process—whether the genotypic and phenotypic features of the cells are significantly altered in this case, and, if so, whether these changes are environmentally hazardous. Our molecular genetic studies have identified six single nucleotide variants, six insertions, and five deletions, which are most likely significant changes after plasma treatment. It was also found that out of 19 tested hydrolytic enzymes, 10 revealed activity, of which nine temporarily decreased their activity and one (naphthol-AS-BI- phosphohydrolase) permanently increased activity as a result of the plasma treatment. In turn, carbon assimilation and drug susceptibility were not affected by plasma. Based on the performed studies, it can be concluded that the observed changes in C. albicans cells that survived the plasma action are not of significant importance to the environment, especially for the drug resistance and pathogenicity of this fungus.

Verified
Journal Article
Open access
PDF file
TKTadeusz Kałużewski
Tadeusz Kałużewski
GPGrzegorz Przybylski
Grzegorz Przybylski
MBMichał Bednarek
Michał Bednarek
SGSławomir Glazar
Sławomir Glazar
MGMagdalena Grabiec
Magdalena Grabiec
Bogdan KałużewskiBogdan Kałużewski
Bogdan Kałużewski
Bladder cancer is one of the most common cancers in global statistics. One of the issues associated with this disease is the high incidence of cases with delayed diagnosis and what factors correlate with worse treatment outcomes. A possible reason for this may be the rather limited availability of non-invasive diagnostic tools. This short communication presents a case of a 68 year old male patient after an ineffective therapy, carried on for several years with symptoms commonly associated with prostate overgrowth that masked a carcinoma in situ of the urinary bladder. Implementation of several diagnostic techniques, including urine sediment cytology, immunocytochemistry, the fluorescence in situ hybridisation technique, the Bladder EpiCheck test and whole-genome sequencing, enabled the establishment of a correct diagnosis, implementation of appropriate treatment and provision of patient-friendly monitoring. The described case emphasises the usefulness of cell-based and liquid-based urine tests in bladder cancer diagnostic procedures.

Verified
Journal Article
Open access
PDF file
TKTadeusz Kałużewski
Tadeusz Kałużewski
IKIzabela Kubiak
Izabela Kubiak
MBMichał Bednarek
Michał Bednarek
JSJordan Sałamunia
Jordan Sałamunia
DKDorota Kucharska
Dorota Kucharska
Bogdan KałużewskiBogdan Kałużewski
Bogdan Kałużewski
Over a 46-month period, the objectives of the National Cancer Control Program (NCCP, pol. Narodowy Program Zwalczania Chorób Nowotworowych), coordinated by the Ministry of Health, were pursued by conducting genetic diagnostics on individuals at high risk of developing cancer. A total of 1097 individuals were enrolled in the study, leading to the identification of 128 cases of germline mutations. The implementation of the NCCP led to the identification of genetic mutations in 4.43% of the patients qualified for BRCA1 and BRCA2 screening tests, in 18.18% of those qualified for a comprehensive next-generation sequencing (NGS) panel in cases of breast and ovarian cancer, and in 17.36% of cases of colorectal and endometrial cancer. The research conducted allowed us to establish individualized preventive and therapeutic approaches for mutation carriers. However, the results prove that liberalizing the inclusion criteria for high-throughput diagnostics and the use of broad gene panels could significantly increase the percentage of detected carriers. This publication serves as a summary and discussion of the results obtained from the implementation of the NCCP as well as of the role of genetic consulting in personalized medicine.